spacer
home > ict > spring 2017 > needle in a haystack
PUBLICATIONS
International Clinical Trials

Needle in a Haystack

If there is one hot zone in drug development, it is the area of rare diseases. Formerly the province of small biotechnology companies and pharmaceutical startups, this area is now attracting the attention of increasingly bigger players, as most recently exemplified by Shire’s establishment of a separate rare disease innovation hub in Cambridge, Massachusetts, US. As we have moved beyond the blockbuster era, and with the declining productivity of Big Pharma pipelines, many larger firms are looking to rare diseases as a potential alternate revenue stream – hence the increased pace of partnering and acquisition activity, as well as efforts to expand ‘organically’ into the field.

Despite the rush of entrants into the category, conducting clinical trials in this area remains a complex proposition. Much of the difficulty is derived from the fact that many rare diseases are not as well understood as more common ailments like diabetes and hypertension. The relatively small patient populations often do not easily lend themselves to defining efficacy endpoints, inclusion and exclusion criteria or other study design elements. Such a lack of clarity makes it especially difficult to devise a protocol that will meet the FDA’s scrutiny, and could even discourage people from participating.

Incentives and Challenges

Nevertheless, pharmaceutical developers have numerous motivations for conducting these studies, including Prescription Drug User Fee Act waivers, tax credits and extended exclusivity for orphan treatments; these can give companies extra time to recoup trial-associated costs. That said, many start small – initially focusing on indications with small patient populations, which may be a springboard to expanded indications or, if they are lucky, off-label usage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Scott Treiber, PhD, MBA, is Executive Vice President of Biopharmaceutical Development at Chiltern and oversees all aspects of biopharmaceutical development including Phase 1-4 trials across a wide range of therapeutic areas. Before joining Chiltern, he held Vice President positions at Theorem, inVentiv Health, Hospira and PharmaNet. Scott is on the board of the Center for Healthcare Innovation.
spacer
Scot Treiber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

GE Healthcare advances the delivery of cell therapies with new thawing technology


More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

8th Clinical Quality Oversight Forum 2017

11-13 October 2017, Sheraton Philadelphia Downtown Hotel, Philadelphia, PA

ExL’s Clinical Quality Oversight Forum continues to live up to its reputation as an elite gathering of senior-level executives.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement